Business Context and Reporting Period
The filing is an August 14, 2023 Form 8-K filed by Tivic Health Systems, Inc., although the request metadata identifies Valion Bio, Inc. The filing reports actions at the August 11, 2023 Special Meeting of Stockholders and references financial results for the second quarter ended June 30, 2023.
Tivic Health Systems develops and commercializes health technology products. The company’s common stock trades on Nasdaq under the symbol TIVC.
Financial and Operating Metrics
The filing states that a press release regarding second-quarter 2023 financial results was issued on August 14, 2023 and furnished as Exhibit 99.1. The provided filing text does not include the press release’s financial details.
- Revenue: The filing text does not provide a clear value.
- Net income or loss: The filing text does not provide a clear value.
- Cash flow, cash balance, liquidity, debt, and margins: The filing text does not provide clear values.
- Guidance or quantified operating outlook: The filing text does not provide a clear value.
Material Changes and Corporate Actions
- At the August 11, 2023 special meeting, holders representing 36,286,719 shares, or approximately 58.4% of the 62,177,734 outstanding shares, were present or represented by proxy, establishing a quorum.
- Stockholders approved authorizing the board to effect a reverse stock split at a ratio between 1-for-5 and 1-for-100. The board may determine the ratio and timing within 12 months without further stockholder approval.
- Proposal 1 received 32,939,351 votes for, 797,381 against, and 2,550,259 abstentions. There were no broker non-votes.
- Stockholders also approved authorizing the board to adjourn the meeting to solicit additional proxies for Proposal 1. The proposal received 32,903,493 votes for, 723,184 against, and 2,660,314 abstentions, with no broker non-votes.
Outlook, Risks, and Unusual Items
The filing contains customary forward-looking statement language. Management cautions that actual results may differ materially because of known and unknown risks, uncertainties, and other factors described in the filing and the company’s other SEC filings.
The approved reverse split is a material corporate action that could affect the company’s share count, trading price, and capital-raising flexibility. The filing does not state whether the board had selected a specific ratio or effective date as of the filing date.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the second-quarter 2023 revenue, loss, cash flow, cash balance, debt, and management commentary.
- Confirm the final reverse-split ratio, effective date, treatment of fractional shares, and resulting share count.
- Review the company’s latest periodic filing for liquidity, going-concern considerations, financing needs, and dilution risks.
- Reconcile the issuer identity: the supplied filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.